Efficacy and Safety of LongShengZhi Capsule on Functional Recovery After Acute Ischaemic Stroke (LONGAN)
NCT ID: NCT05277311
Last Updated: 2022-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
1376 participants
INTERVENTIONAL
2022-05-01
2024-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Tongxinluo Capsule in Ischemic Stroke Patients（TISS)
NCT01919671
Evaluation of Xueshuantong in Patients With AcutE IschemiC STroke
NCT04415164
Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke
NCT00710164
Efficacy and Safety of Qizhitongluo Capsule in the Recovery Phase of Ischemic Stroke
NCT01762163
Intracerebral Transplantation of Neural Stem Cells for the Treatment of Ischemic Stroke
NCT03296618
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
LongShengZhi capsule
Experimental group
LongShengZhi capsule
LongShengZhi capsules, orally, 5 capsules each time, three times a day.
LongShengZhi capsule placebo
Placebo group
LongShengZhi capsule placebo
LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
LongShengZhi capsule
LongShengZhi capsules, orally, 5 capsules each time, three times a day.
LongShengZhi capsule placebo
LongShengZhi capsules placebo, orally, 5 capsules each time, three times a day.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 18 years of age or older, and gender not limited
* NIHSS score of 4 to 15
Exclusion Criteria
* Pre-stroke mRS score of more than 1
* Known severe liver or kidney dysfunction
* Known allergies for ingredients in the investigational product
* Known bleeding diathesis or coagulation disorder
* Known medical condition likely to limit survival to less than 3 months
* Pregnant women (clinically evident) or breastfeeding women
* Participation in any investigational study in the previous 3 months
* Known dementia, uncontrolled psychiatric problems
* Any condition that could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study. The judgment is left to the discretion of the investigator
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dongzhimen Hospital, Beijing
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ying Gao
Professor
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HX-DZM-202119
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.